Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA (2017) Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European thoracic oncology platform (ETOP) lungscape project. Lung Cancer 111:143–149

Article  PubMed  Google Scholar 

Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN and R. S. Heist. 2021. A phase 2 study of Capmatinib in patients with MET-Altered Lung Cancer previously treated with a MET inhibitor. J Thorac Oncol 16 (5):850–859

Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T (2019) Sensitivity and resistance of MET exon 14 mutations in Lung Cancer to eight MET tyrosine kinase inhibitors in Vitro. J Thorac Oncol 14(10):1753–1765

Article  CAS  PubMed  Google Scholar 

Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17(9):569–587

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z, Jin R, Le X, Li W, Xia Y (2024) Targeting MET in NSCLC: an ever-expanding territory. JTO Clin Res Rep 5 (2)

Kang J, Chen HJ, Wang Z, Liu J, Li B, Zhang T, Yang Z, Wu YL, Yang JJ (2018) Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to Crizotinib. J Thorac Oncol 13(4):e49–e53

Article  PubMed  Google Scholar 

Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, Liang Z, Cheng Y, Jiang L, Yang N, Han Z, Shi J, Chen Y, Xu H, Zhang H, Chen G, Ma R, Sun S, Fan Y, Li J, Luo X, Wang L, Ren Y, Su W (2021) Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med 9(10):1154–1164

Article  CAS  PubMed  Google Scholar 

Piper-Vallillo AJ, Halbert BT, Rangachari D, Kobayashi SS, Costa DB (2020) Acquired Resistance to Osimertinib Plus Savolitinib is mediated by MET-D1228 and MET-Y1230 mutations in EGFR-Mutated MET-Amplified Lung Cancer. JTO Clin Res Rep 1(4):100071

PubMed  PubMed Central  Google Scholar 

Tang XY, Wu S, Wang D, Chu C, Hong Y, Tao M, Hu H, Xu M, Guo X, Liu Y (2022) Human organoids in basic research and clinical applications. Signal Transduct Target Ther 7(1):168

Article  PubMed  PubMed Central  Google Scholar 

Wang S, Du M, Zhang J, Xu W, Yuan Q, Li M, Wang J, Zhu H, Wang Y, Wang C, Gong Y, Wang X, Hu Z, Christiani DC, Xu L, Shen H, Yin R (2020) Tumor evolutionary trajectories during the acquisition of invasiveness in early stage lung adenocarcinoma. Nat Commun 11(1):6083

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS (2020) Capmatinib in MET exon 14-Mutated or MET-Amplified non-small-cell Lung Cancer. N Engl J Med 383(10):944–957

Article  CAS  PubMed  Google Scholar 

Xia Y, Jin R, Li M, Lan F, Zhu H, Yu Y, Miao D, Wang Q, Zhou Y, Selvaggi G, Ying S, Zhang J, Shen H, Le X, Li W (2023) Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer. Cancer Lett 561:216140

Article  CAS  PubMed  Google Scholar 

Yin S, Xi R, Wu A, Wang S, Li Y, Wang C, Tang L, Xia Y, Yang D, Li J, Ye B, Yu Y, Wang J, Zhang H, Ren F, Zhang Y, Shen D, Wang L, Ying X, Li Z, Bu Z, Ji X, Gao X, Jia Y, Jia Z, Li N, Li Z, Ji JF, Xi JJ (2020) Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Sci Transl Med 12 (549)

Yoshida GJ (2020) Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol 13(1):4

Article  PubMed  PubMed Central  Google Scholar 

Yu Y, Ren Y, Fang J, Cao L, Liang Z, Guo Q, Han S, Ji Z, Wang Y, Sun Y, Chen Y, Li X, Xu H, Zhou J, Jiang L, Cheng Y, Han Z, Shi J, Chen G, Ma R, Fan Y, Sun S, Jiao L, Jia X, Wang L, Lu P, Xu Q, Luo X, Su W, Lu S (2022) Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study. Therapeutic Adv Med Oncol 14:17588359221133546

CAS  Google Scholar